首页> 美国卫生研究院文献>Journal of Lipid Research >Thematic Review Series: Recent Advances in the Treatment of Lysosomal Storage Diseases: Lysosomal exocytosis and lipid storage disorders
【2h】

Thematic Review Series: Recent Advances in the Treatment of Lysosomal Storage Diseases: Lysosomal exocytosis and lipid storage disorders

机译:专题回顾系列:溶酶体贮积病治疗的最新进展:溶酶体胞吐和脂质贮积病

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Lysosomes are acidic compartments in mammalian cells that are primarily responsible for the breakdown of endocytic and autophagic substrates such as membranes, proteins, and lipids into their basic building blocks. Lysosomal storage diseases (LSDs) are a group of metabolic disorders caused by genetic mutations in lysosomal hydrolases required for catabolic degradation, mutations in lysosomal membrane proteins important for catabolite export or membrane trafficking, or mutations in nonlysosomal proteins indirectly affecting these lysosomal functions. A hallmark feature of LSDs is the primary and secondary excessive accumulation of undigested lipids in the lysosome, which causes lysosomal dysfunction and cell death, and subsequently pathological symptoms in various tissues and organs. There are more than 60 types of LSDs, but an effective therapeutic strategy is still lacking for most of them. Several recent in vitro and in vivo studies suggest that induction of lysosomal exocytosis could effectively reduce the accumulation of the storage materials. Meanwhile, the molecular machinery and regulatory mechanisms for lysosomal exocytosis are beginning to be revealed. In this paper, we first discuss these recent developments with the focus on the functional interactions between lipid storage and lysosomal exocytosis. We then discuss whether lysosomal exocytosis can be manipulated to correct lysosomal and cellular dysfunction caused by excessive lipid storage, providing a potentially general therapeutic approach for LSDs.
机译:溶酶体是哺乳动物细胞中的酸性区室,主要负责将内吞性和自噬性底物(如膜,蛋白质和脂质)分解为其基本结构单元。溶酶体贮积病(LSD)是由代谢分解所需的溶酶体水解酶的基因突变,对分解代谢产物输出或膜运输重要的溶酶体膜蛋白突变或间接影响这些溶酶体功能的非溶酶体蛋白突变引起的一组代谢紊乱。 LSD的标志性特征是溶酶体中未消化脂质的主要和次要过度积累,这会导致溶酶体功能障碍和细胞死亡,并随后在各种组织和器官中引起病理症状。 LSD的类型超过60种,但是对于大多数LSD仍然缺乏有效的治疗策略。最近的一些体外和体内研究表明,溶酶体胞吐作用的诱导可有效减少储存材料的积累。同时,溶酶体胞吐作用的分子机制和调控机制开始被揭示。在本文中,我们首先讨论这些最新进展,重点是脂质存储和溶酶体胞吐作用之间的功能相互作用。然后,我们讨论是否可以操纵溶酶体胞吐作用以纠正由过多脂质存储引起的溶酶体和细胞功能障碍,从而为LSD提供潜在的一般治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号